$203.73
0.15% day before yesterday
NYSE, Sep 06, 10:10 pm CET
ISIN
US70975L1070
Symbol
PEN
Sector

Penumbra, Inc. Stock price

$203.73
+32.29 18.83% 1M
-45.72 18.33% 6M
-47.81 19.01% YTD
-75.33 26.99% 1Y
-73.77 26.58% 3Y
+71.91 54.55% 5Y
+162.43 393.29% 10Y
NYSE, Closing price Fri, Sep 06 2024
-0.31 0.15%
ISIN
US70975L1070
Symbol
PEN
Sector

Key metrics

Market capitalization $7.91b
Enterprise Value $7.80b
P/E (TTM) P/E ratio 595.01
EV/FCF (TTM) EV/FCF 70.51
EV/Sales (TTM) EV/Sales 6.88
P/S ratio (TTM) P/S ratio 6.98
P/B ratio (TTM) P/B ratio 6.81
Revenue growth (TTM) Revenue growth 20.89%
Revenue (TTM) Revenue $1.13b
EBIT (operating result TTM) EBIT $73.95m
Free Cash Flow (TTM) Free Cash Flow $110.67m
Cash position $339.70m
EPS (TTM) EPS $0.34
P/E forward 486.73
P/S forward 6.66
EV/Sales forward 6.57
Short interest 9.99%
Show more

Is Penumbra, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Penumbra, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Penumbra, Inc. forecast:

12x Buy
67%
6x Hold
33%

Analyst Opinions

18 Analysts have issued a Penumbra, Inc. forecast:

Buy
67%
Hold
33%

Financial data from Penumbra, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
1,134 1,134
21% 21%
100%
- Direct Costs 435 435
22% 22%
38%
699 699
20% 20%
62%
- Selling and Administrative Expenses 500 500
14% 14%
44%
- Research and Development Expense 92 92
14% 14%
8%
106 106
71% 71%
9%
- Depreciation and Amortization 32 32
25% 25%
3%
EBIT (Operating Income) EBIT 74 74
104% 104%
7%
Net Profit 14 14
51% 51%
1%

In millions USD.

Don't miss a Thing! We will send you all news about Penumbra, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Penumbra, Inc. Stock News

Neutral
PRNewsWire
11 days ago
ALAMEDA, Calif. , Aug. 27, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Baird Global Healthcare Conference on Tuesday, September 10, 2024.
Neutral
PRNewsWire
17 days ago
ALAMEDA, Calif. , Aug. 21, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Wells Fargo Healthcare Conference on Wednesday, September 4, 2024.
Neutral
Seeking Alpha
19 days ago
Penumbra is continuing to take share with its new CAVT devices against its closest competition in the VTE space. PEN reduced guidance after Q2 earnings, but the market took it in stride, with difficult comparisons against 2023. PEN has recently announced a supportive $200m buyback, which will put a floor under the shares here.
More Penumbra, Inc. News

Company Profile

Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers thrombectomy, embolization, access, neurosurgical tools, ruby coil system, lantern, penumbra occlusion device (POD) system, packing coil, and indigo systems products. Its target markets include interventional neuroradiologists, neurosurgeons, and interventional neurologists; and interventional radiologists, vascular surgeons, and interventional cardiologists. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.

Head office United States
CEO Adam Elsesser
Employees 4,200
Founded 2004
Website www.penumbrainc.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today